Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

January 9, 2020 by Alan Khadavi

Delgocitinib for patients with atopic dermatitis

Topical delgocitinib (JTE-052) is a novel Janus kinase inhibitor that has been shown to be effective in adults with eczema. Eczema is an itchy, inflammatory skin rash that lasts chronically and it can fluctuate.  It is seen more in childhood and the majority of patients experience resolution with age.

The goal of treatment is to minimize symptoms with minimal pharmacologic intervention.  Currently topical steroids and calcineurin inhibitors (Elidel, Protopic) form the mainstay of controlling skin inflammation. Long term usage of steroids though can lead to safety concerns such as skin atrophy.  Other topical treatments can cause irritation at the application site.

Atopic Dermatitis (Eczema) Treatment

Treatment of Atopic Dermatitis (Eczema)

New therapies are needed in patients, especially in pediatrics. Numerous immunologic pathways are involved in atopic dermatitis. One pathway, the Janus kinase (JAK) can lead to inflammatory factors. Delgocitinib is a JAK inhibitor under development in Japan by Torii Pharmaceutical. A recent Phase 2 study examined delgocitinib ointment in pediatric patients with atopic dermatitis.

Patients were between 2-15 years of age and received 0.25% or 0.5% delgocitinib twice daily for 4 weeks. The results showed:

  • Skin inflammation and itching scores in both delgocitinib groups were significantly improved compared with those in the placebo group at the end of treatment.
  • Delgocitinib ointment was well tolerated during the 4 week treatment period.

Janus kinase inhibitors are a potential therapeutic option for patients with eczema. Dupilumab, an inhibitor of both IL-4 and IL-13 has been approved for eczema.  Nemolizumab, an inhibitor of IL-31 signaling, has received attention for its anti-itching effects.

In addition to the anti-inflammatory effect, delgocitinib ointment has a promoting effect on the production of filaggrin, which plays an important role in skin barrier function.

Side effects from delgocitinib were minimal in the study, some adverse effects that were seen were, nasopharyngitis, impetigo and urticaria. No irritation or burning sensations were seen. Because this was a small short study, comparing delgocitinib with other topical steroids, tacrolimus or Eucrisa should not be done. Because eczema requires long term treatment, a phase 3 long term study will need to be done.  Other Janus kinase topical inhibitors being studied are tofacitinib and ruxolitinib.

Overall, delgocitinib ointment markedly and rapidly improved clinical signs and symptoms in patients with atopic dermatitis. It was well tolerated and it may be a promising therapeutic option.

————————————————————————————————————————————

Update August 6, 2025

On July 23, 2025, the U.S. Food and Drug Administration granted approval for Anzupgo (generic name delgocitinib)—the first and only FDA‑approved topical therapy for moderate to severe chronic hand eczema (CHE) in adults who haven’t responded adequately to topical corticosteroids or for whom steroid use isn’t recommended.


What Is Chronic Hand Eczema?

Chronic hand eczema is defined as eczema lasting at least three months or relapsing twice or more in a year. It affects roughly 1 in 10 adults worldwide, characterized by:

  • Intense itching and pain

  • Visible skin changes: erythema, blistering, lichenification, fissures, edema

This condition seriously impacts daily life—tasks like washing dishes, opening jars, or even social contact through handshakes may become painful and isolating.


How Anzupgo Works

Anzupgo is a topical pan‑JAK inhibitor, targeting all four key Janus kinase enzymes: JAK1, JAK2, JAK3, and TYK2. By inhibiting JAK‑STAT signaling, it disrupts inflammatory pathways central to CHE.

Why it’s significant:

  • Steroid-free—offers a non‑corticosteroid alternative for long‑term use.

  • Broad subtype coverage—cleared all subtypes of CHE in clinical trials.


Evidence from Clinical Trials

Approval was based on two pivotal phase 3 DELTA trials (DELTA‑1 and DELTA‑2), enrolling approximately 960 adults with moderate to severe CHE.

  • Primary Endpoint (Week 16): Investigator Global Assessment for CHE (IGA‑CHE).

    • DELTA‑1: 20% of Anzupgo users achieved “clear” or “almost clear” vs 10% on vehicle (p = .006).

    • DELTA‑2: 29% vs 7% (p < .0001).

  • Symptom Relief:

    • Around 49% of Anzupgo-treated patients in both trials achieved ≥ 4‑point reductions in pain and itch vs 23‑28% on vehicle (p < .0001)

  • Long‑term Use: An open‑label extension (DELTA‑3, up to 52 weeks) confirmed sustained efficacy and a reassuring safety profile.


Safety Profile & Usage Guidelines

Dosage & Administration:

  • Apply a thin layer twice daily to affected hands and wrists only.

  • Maximum: 30 g per 2 weeks or 60 g per month.

Warnings & Precautions:

  • Avoid combining with other JAK inhibitors or strong immunosuppressants.

  • Monitor for potential side effects: application‑site pain, erythema, pruritus, paresthesia, and rare bacterial skin infections (e.g. paronychia, cellulitis). Also monitor blood counts—leukopenia/neutropenia possible. Slight elevation in non‑melanoma skin cancer risk has been noted.

  • Vaccinations: Patients should be up‑to‑date on immunizations (e.g. herpes zoster) before initiating therapy.FDA Access Data


Why This Matters

  • Unmet Need: Until Anzupgo’s approval, no FDA‑approved treatments existed specifically for CHE in the U.S., leaving many patients reliant on off‑label or systemically riskier options.

  • Expert Perspectives:

    • LEO Pharma executives emphasize Anzupgo’s potential to fill a long‑standing treatment gap in dermatology.

    • The National Eczema Association highlights its significance as a major milestone and source of hope for patients.

Filed Under: atopic dermatitis, Blog, Pediatric

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page